Table 5.
Group | n | AI (%) | Go-G1 (%) | S-phase (%) | G2-M (%) |
Control | 3 | 0.28±0.05 | 68.40±6.47 | 1.82±0.33 | 29.76±6.80 |
Hepatic fibrosis | 3 | 1.63±0.25a | 62.27±17.96 | 9.83±1.81a | 23.26±10.95 |
Non-DSHX-treated | 3 | 1.78±0.43a | 50.53±2.25 | 11.87±1.92a | 13.60±1.15 |
DSHX-treated | 3 | 7.81±0.47ce | 94.30±1.33ce | 3.11±1.27ce | 2.58±0.73df |
P<0.05 vs normal control group;
P<0.05,
P<0.01 vs hepatic fibrosis group;
P<0.05 ,
P<0.01 vs non-DSHX-treated group.